On June 8-10, CombiGene’s Preclinical Project Manager Annika Ericsson will participate in Next Generation Gene Therapy Vectors.
”I look forward to an exciting conference on the next generation of gene therapy vectors and to discuss limitations that current gene therapy vectors have, including immunogenicity, toxicity and safety”, says Annika.
CombiGene is always looking for more knowledge!
Gene therapy is a very dynamic area where new knowledge is generated on a daily basis. By participating in national and international congresses and conferences, CombiGene gets to take part in knowledge development and establish important new contacts.
The easiest way to get in touch with Annika is on her email:
Du kommer enklast i kontakt med Annika på hennes email:
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.